Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CHFS

Nuwellis (CHFS) Stock Price, News & Analysis

Nuwellis logo

About Nuwellis Stock (NASDAQ:CHFS)

Advanced Chart

Key Stats

Today's Range
$5.07
$5.25
50-Day Range
$3.53
$6.02
52-Week Range
$4.86
$37.50
Volume
22,026 shs
Average Volume
467,323 shs
Market Capitalization
$31.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CHFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuwellis and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CHFS Stock News Headlines

Nuwellis Gains FDA Clearance for New Catheter
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
Nuwellis Appoints John L. Erb as CEO
See More Headlines

CHFS Stock Analysis - Frequently Asked Questions

Nuwellis, Inc. (NASDAQ:CHFS) issued its quarterly earnings results on Monday, March, 1st. The company reported ($1.57) EPS for the quarter, topping analysts' consensus estimates of ($1.91) by $0.34. The company had revenue of $2.04 million for the quarter. Nuwellis had a negative trailing twelve-month return on equity of 173.61% and a negative net margin of 254.26%.

Nuwellis shares reverse split on the morning of Friday, October 13th 2017.The 1-20 reverse split was announced on Thursday, October 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 12th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nuwellis investors own include Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Biocept (BIOC), VBI Vaccines (VBIV), Prima BioMed (IMMP), NightHawk Biosciences (NHWK) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
3/01/2021
Today
8/29/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Electromedical Equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:CHFS
Previous Symbol
NASDAQ:SSH
CIK
1506492
Fax
N/A
Employees
66
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($279.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.11 million
Net Margins
-254.26%
Pretax Margin
N/A
Return on Equity
-173.61%
Return on Assets
-131.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.87
Quick Ratio
5.97

Sales & Book Value

Annual Sales
$5.51 million
Price / Sales
5.68
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$12.79 per share
Price / Book
0.41

Miscellaneous

Outstanding Shares
6,037,000
Free Float
N/A
Market Cap
$31.27 million
Optionable
Not Optionable
Beta
1.55
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:CHFS) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners